Tissue Regenix Group (TRX.L) Stock Price
£40.5 0%
to add to portfolio
AI Score
-
Alternative
6 -
Fundamental
1 -
Technical
1
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Tissue Regenix Group, AI stock picks, stock alerts and much more.
TRX.L AI Stock Analysis
AI stock analysis for TRX.L is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Tissue Regenix Group (TRX.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Tissue Regenix Group (TRX.L) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Tissue Regenix Group (TRX.L), currently trading at £40.5, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About TRX.L
-
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally.
-
Symbol
TRX.L
-
Market
LSE
-
Industry
Biotechnology
-
Market Cap
28.8M
Similar Stocks
 |
Codexis 0I0X.L |
$2.7 6% |
3 |
 |
Oxford Nanopore Technologies plc ONT.L |
£115 4.6% |
4 |
 |
Sareum Holdings SAR.L |
£12.5 0.00% |
3 |
 |
Viridian Therapeutics 0K1R.L |
$15.26 4.2% |
5 |
 |
Avacta Group Plc AVCT.L |
£42 2.4% |
3 |
News
TRX.L Alternative Data
Web Traffic
Tissue Regenix Group receives an estimated 520 monthly visitors to tissueregenix.com.
-
Web Traffic
520
-
Change from Previous Month
7%
-
3 Month Change
71.8%
-
YoY Change
71.8%
News Mentions
Tissue Regenix Group was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Twitter Followers
Tissue Regenix Group has 73 Twitter Followers on its main Twitter (also known as X) account, which is up by 5.8% over the last month.
-
Twitter Followers
73
-
Daily Change
0%
-
1 Month Change
5.8%
-
3 Month Change
9%
Youtube Subscribers
Tissue Regenix Group has 13 subscribers on its main Youtube channel.
-
Youtube Subscribers
13
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
LinkedIn Followers
4,235 are following Tissue Regenix Group on LinkedIn, up by 1.4% over the last month.
-
LinkedIn Followers
4235
-
Daily Change
0%
-
1 Month Change
1.4%
-
3 Month Change
3.6%
LinkedIn Employees
According to LinkedIn, Tissue Regenix Group has 46 employees, up by 2.2% over the last month.
-
LinkedIn Employees
46
-
Daily Change
0%
-
1 Month Change
2.2%
-
3 Month Change
2.2%
Reddit Mentions
Tissue Regenix Group has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
TRX.L Financials
TRX.L Key Metrics
-
Total Revenue
$13M
-
Net Income
-$222.2K
-
Earnings per Share
-$0.0031
-
Free cash flow
-$1.6M
-
EBITDA
$828.6K
-
EBITDA Ratio
0.0638946
-
Total Assets
$43.2M
TRX.L 2-year Revenue & Income
TRX.L 2-year Free Cash Flow
TRX.L Technicals
TRX.L SMA
TRX.L RSI
FAQ
What's the current price of Tissue Regenix Group (TRX.L) Stock?
The price of an Tissue Regenix Group (TRX.L) share is £40.5.
What's the market cap of Tissue Regenix Group?
The current market cap of Tissue Regenix Group is 28.8M.
Should I buy or sell TRX.L?
Tissue Regenix Group shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Tissue Regenix Group is better viewed as a hold or accumulate position while waiting for further developments.
Is Tissue Regenix Group a good investment?
The current analysis of Tissue Regenix Group's fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Tissue Regenix Group's portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Tissue Regenix Group (TRX.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Tissue Regenix Group stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Tissue Regenix Group (TRX.L) that investors often compare it to?
Tissue Regenix Group (TRX.L) is often compared to similar stocks such as Codexis, Oxford Nanopore Technologies plc, Sareum Holdings, Viridian Therapeutics and Avacta Group Plc.
What is the forecast for Tissue Regenix Group's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Tissue Regenix Group's stock price to be around £38.37 in 2026. Starting from the current price of £40.5, this represents a 5.3% change in price, indicating a bearish outlook for the stock.
How to buy Tissue Regenix Group (TRX.L) Stock?
Tissue Regenix Group stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Tissue Regenix Group shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.